Literature DB >> 8627665

Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic.

A Nath1, K Psooy, C Martin, B Knudsen, D S Magnuson, N Haughey, J D Geiger.   

Abstract

Tat is an 86- to 104-amino-acid viral protein that activates human immunodeficiency virus type 1 expression, modifies several cellular functions, and causes neurotoxicity. Here, we determined the extent to which peptide fragments of human immunodeficiency virus type 1 BRU Tat1-86 produced neurotoxicity, increased levels of intracellular calcium ([Ca2+]i), and affected neuronal excitability. Tat31-61 but not Tat48-85 dose dependently increased cytotoxicity and levels of [Ca2+]i in cultured human fetal brain cells. Similarly, Tat31-61 but not Tat48-85 depolarized rat hippocampal CA1 neurons in slices of rat brain. The neurotoxicity and increases in [Ca2+]i could be significantly inhibited by non-N-methyl-D-aspartate excitatory amino acid receptor antagonists. Shorter 15-mer peptides which overlapped by 10 amino acids each and which represented the entire sequence of Tat1-86 failed to produce any measurable neurotoxicity. Although it remains to be determined if Tat acts directly on neurons and/or indirectly via glial cells, these findings do suggest that Tat neurotoxicity is conformationally dependent, that the active site resides within the first exon of Tat between residues 31 to 61, and that these effects are mediated at least in part by excitatory amino acid receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627665      PMCID: PMC189968     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Activity of synthetic tat peptides in human immunodeficiency virus type 1 long terminal repeat-promoted transcription in a cell-free system.

Authors:  J Jeyapaul; M R Reddy; S A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Epidemiology of human immunodeficiency virus encephalopathy in the United States.

Authors:  R S Janssen; O C Nwanyanwu; R M Selik; J K Stehr-Green
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

3.  HIV-1 Nef protein exhibits structural and functional similarity to scorpion peptides interacting with K+ channels.

Authors:  T Werner; S Ferroni; T Saermark; R Brack-Werner; R B Banati; R Mager; L Steinaa; G W Kreutzberg; V Erfle
Journal:  AIDS       Date:  1991-11       Impact factor: 4.177

Review 4.  Pathology of HIV-1 infection of the central nervous system. A review.

Authors:  L R Sharer
Journal:  J Neuropathol Exp Neurol       Date:  1992-01       Impact factor: 3.685

5.  Structural studies of HIV-1 Tat protein.

Authors:  P Bayer; M Kraft; A Ejchart; M Westendorp; R Frank; P Rösch
Journal:  J Mol Biol       Date:  1995-04-07       Impact factor: 5.469

6.  Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia.

Authors:  A Ranki; M Nyberg; V Ovod; M Haltia; I Elovaara; R Raininko; H Haapasalo; K Krohn
Journal:  AIDS       Date:  1995-09       Impact factor: 4.177

7.  Lethal neurotoxicity in mice of the basic domains of HIV and SIV Rev proteins. Study of these regions by circular dichroism.

Authors:  K Mabrouk; J Van Rietschoten; E Vives; H Darbon; H Rochat; J M Sabatier
Journal:  FEBS Lett       Date:  1991-09-02       Impact factor: 4.124

8.  Low levels of human immunodeficiency virus replication in the brain tissue of children with severe acquired immunodeficiency syndrome encephalopathy.

Authors:  R Vazeux; C Lacroix-Ciaudo; S Blanche; M C Cumont; D Henin; F Gray; L Boccon-Gibod; M Tardieu
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

9.  Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion.

Authors:  M Tardieu; C Héry; S Peudenier; O Boespflug; L Montagnier
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

10.  Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain.

Authors:  B S Weeks; D M Lieberman; B Johnson; E Roque; M Green; P Loewenstein; E H Oldfield; H K Kleinman
Journal:  J Neurosci Res       Date:  1995-09-01       Impact factor: 4.164

View more
  127 in total

1.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

Review 2.  Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility.

Authors:  Megan K Patrick; James B Johnston; Christopher Power
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 3.  Functional roles of HIV-1 Tat protein in the nucleus.

Authors:  Yana R Musinova; Eugene V Sheval; Carla Dib; Diego Germini; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2015-10-27       Impact factor: 9.261

4.  HIV-1 Protein Tat1-72 Impairs Neuronal Dendrites via Activation of PP1 and Regulation of the CREB/BDNF Pathway.

Authors:  Yu Liu; Deyu Zhou; Jiabin Feng; Zhou Liu; Yue Hu; Chang Liu; Xiaohong Kong
Journal:  Virol Sin       Date:  2018-05-08       Impact factor: 4.327

Review 5.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

6.  Unconjugated TAT carrier peptide protects against excitotoxicity.

Authors:  Anne Vaslin; Coralie Rummel; Peter G H Clarke
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

7.  The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures.

Authors:  Bruno P Meloni; Amanda J Craig; Nadia Milech; Richard M Hopkins; Paul M Watt; Neville W Knuckey
Journal:  Cell Mol Neurobiol       Date:  2013-11-09       Impact factor: 5.046

Review 8.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

9.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

10.  Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.

Authors:  Mahmoud L Soliman; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.